touchONCOLOGY joins Dr Valsamo Anagnostou (Johns Hopkins University School of Medicine, Baltimore, MD, USA ) at WCLC 2021 to discuss her presentation on the circulating tumor DNA biomarker-directed blood test and immune checkpoint inhibitor therapy in people with advanced non-small cell lung cancer.
Clinical Trial Registry Identifiers: CRI-CCTG0002/BR.36, NCT04093167.
1. What are the major challenges of immune checkpoint inhibitor therapy in people with advanced non-small cell lung cancer? (00:10-01:36)
2. Could you tell us a little about the circulating tumor DNA biomarker-directed blood test, and the clinical evidence supporting its use? (01:36-03:39)
3. What were the aims, design and patient population of your phase II study? (03:39-05:55)
4. What are the primary outcome measures planned for this study? (05:55-06:45)
5. What future studies are planned? (06:45-08:18)
Disclosures: Valsamo Anagnostou receives research funding from Bristol Myers Squibb and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
Share this Video
Related Videos In Lung Cancer
Paula Ugalde, WCLC 2021: Screening, Incidental Nodules, and Adjuvant Therapy for Early-Stage Lung Cancer
touchONCOLOGY joins Dr Paula Ugalde (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) at WCLC 2021 to discuss her presentation on screening, incidental nodules and adjuvant therapy for early-stage lung cancer. Questions 1. Early detection of lung cancer improves disease outcomes – when and in which patients do you perform screening? (00:15-00:46) 2. […]
Antoinette Wozniak, WCLC 2021: Important Recent Developments in the Diagnosis and Management of Small Cell Lung Cancer
touchONCOLOGY joins Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss the challenges of treating small cell lung cancer and the most important recent advances. Questions 1. Please can you outline the current prognosis for patients with small cell lung cancer (SCLC)? (00:26-02:37) 2. In your opinion, what are […]
Antoinette Wozniak, WCLC 2021: Highlights of the digital 2021 conference
touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year. Question What have been your particular highlights of the World Conference on Lung Cancer 2021? Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!